251 related articles for article (PubMed ID: 2021973)
21. A novel role for MHC class II antigens: evidence implicating a protective effect on tumour cells against cytotoxicity by NK and LAK cells.
Lobo PI; Patel HC
Immunology; 1994 Oct; 83(2):240-4. PubMed ID: 7835941
[TBL] [Abstract][Full Text] [Related]
22. Induction of human lymphokine-activated killer cells by IFN-alpha and IFN-gamma.
Ellis TM; McKenzie RS; Simms PE; Helfrich BA; Fisher RI
J Immunol; 1989 Dec; 143(12):4282-6. PubMed ID: 2512355
[TBL] [Abstract][Full Text] [Related]
23. The relationship between multi-drug resistance and resistance to natural-killer-cell and lymphokine-activated killer-cell lysis in human leukemic cell lines.
Treichel RS; Olken S
Int J Cancer; 1992 Jan; 50(2):305-10. PubMed ID: 1370437
[TBL] [Abstract][Full Text] [Related]
24. The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis.
Chang CS; Brossay L; Kronenberg M; Kane KP
J Exp Med; 1999 Feb; 189(3):483-91. PubMed ID: 9927510
[TBL] [Abstract][Full Text] [Related]
25. Characteristics of human T-lymphotropic virus type-1 (HTLV-1)-infected cell line MT-2, which is not killed by a natural killer cell line NK-92 but is killed by lymphokine-activated killer cells.
Komatsu F; Yoshida S
Oncol Res; 1999; 11(5):213-8. PubMed ID: 10608615
[TBL] [Abstract][Full Text] [Related]
26. Activated endothelial cells resist lymphokine-activated killer cell-mediated injury. Possible role of induced cytokines in limiting capillary leak during IL-2 therapy.
Mier JW; Brandon EP; Libby P; Janicka MW; Aronson FR
J Immunol; 1989 Oct; 143(7):2407-14. PubMed ID: 2528594
[TBL] [Abstract][Full Text] [Related]
27. Altered expression of P-glycoprotein and cellular adhesion molecules on human multi-drug-resistant tumor cells does not affect their susceptibility to NK- and LAK-mediated cytotoxicity.
Scheper RJ; Dalton WS; Grogan TM; Schlosser A; Bellamy WT; Taylor CW; Scuderi P; Spier C
Int J Cancer; 1991 Jun; 48(4):562-7. PubMed ID: 1710609
[TBL] [Abstract][Full Text] [Related]
28. Decreased susceptibility of lined human gliosarcoma cells to lymphokine-activated killer cell cytolysis by gamma-interferon treatment.
Miyatake S; Kikuchi H; Oda Y; Nishioka T; Takahashi J; Kondoh S; Matsumoto M; Yamasaki T; Iwasaki K; Aoki T
Cancer Res; 1990 Feb; 50(3):596-600. PubMed ID: 2137025
[TBL] [Abstract][Full Text] [Related]
29. Low-dose human cytomegalovirus infection of human fibroblast cultures induces lymphokine-activated killer cell resistance: interferon-beta-mediated target cell protection does not correlate with up-regulation of HLA class I surface molecules.
Hamprecht K; Steinmassl M
Immunology; 1994 Jun; 82(2):171-7. PubMed ID: 7927485
[TBL] [Abstract][Full Text] [Related]
30. Protection of cultured human monocytes from lymphokine-activated killer-mediated lysis by IFN-gamma.
Blanchard DK; Djeu JY
J Immunol; 1988 Dec; 141(11):4067-73. PubMed ID: 2460557
[TBL] [Abstract][Full Text] [Related]
31. Interferon-gamma-treated K562 target cells distinguish functional NK cells from lymphokine-activated killer (LAK) cells.
Powell J; Stone J; Chan WC; Yang ZD; Leatherbury A; Sell KW; Wiktor-Jedrzejczak W; Ahmed-Ansari A
Cell Immunol; 1989 Feb; 118(2):250-64. PubMed ID: 2491960
[TBL] [Abstract][Full Text] [Related]
32. Intracellular calcium changes associated with in vitro lymphokine-activated killer and natural killer cell cytotoxicity.
Burkey BB; Omann GM; Wolf GT
Arch Otolaryngol Head Neck Surg; 1991 Nov; 117(11):1281-6. PubMed ID: 1747234
[TBL] [Abstract][Full Text] [Related]
33. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells.
Falk CS; Noessner E; Weiss EH; Schendel DJ
Cancer Res; 2002 Jan; 62(2):480-7. PubMed ID: 11809699
[TBL] [Abstract][Full Text] [Related]
34. Elevated prostaglandin E2 production by monocytes is responsible for the depressed levels of natural killer and lymphokine-activated killer cell function in patients with breast cancer.
Baxevanis CN; Reclos GJ; Gritzapis AD; Dedousis GV; Missitzis I; Papamichail M
Cancer; 1993 Jul; 72(2):491-501. PubMed ID: 8319179
[TBL] [Abstract][Full Text] [Related]
35. Hairy cell leukemia cells are relatively NK-insensitive targets.
Starling GC; Nimmo JC; Hart DN
Pathology; 1988 Oct; 20(4):361-5. PubMed ID: 2977221
[TBL] [Abstract][Full Text] [Related]
36. Correlation of class I MHC antigen levels on some human tumor cell lines with susceptibility to LAK cells and performance in cold target inhibition assays.
Haridas V; Saxena RK
Cell Immunol; 1995 Apr; 161(2):256-61. PubMed ID: 7697736
[TBL] [Abstract][Full Text] [Related]
37. Interleukin 2 protects hairy leukemic cells from lymphokine-activated killer cell-mediated cytotoxicity.
Reiter Z; Taylor MW
Cancer Res; 1993 Aug; 53(15):3555-60. PubMed ID: 7687924
[TBL] [Abstract][Full Text] [Related]
38. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms involved in NK resistance induced by interferon-gamma.
Ramirez R; Solana R; Carracedo J; Alonso MC; Peña J
Cell Immunol; 1992 Mar; 140(1):248-56. PubMed ID: 1739986
[TBL] [Abstract][Full Text] [Related]
40. Alpha-interferon and lymphokine-activated killer cells in hairy cell leukemia.
Griffiths SD; Cawley JC
Leukemia; 1988 Jun; 2(6):377-81. PubMed ID: 3374170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
